BR112013002877A2 - tratamento de doenças mitocondriais com naftoquinonas - Google Patents
tratamento de doenças mitocondriais com naftoquinonasInfo
- Publication number
- BR112013002877A2 BR112013002877A2 BR112013002877A BR112013002877A BR112013002877A2 BR 112013002877 A2 BR112013002877 A2 BR 112013002877A2 BR 112013002877 A BR112013002877 A BR 112013002877A BR 112013002877 A BR112013002877 A BR 112013002877A BR 112013002877 A2 BR112013002877 A2 BR 112013002877A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- mitochondrial diseases
- naphthoquinones
- treatment
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
tratamento de doenças mitocondriais com naftoquinonas. métodos de tratar, prevenir ou suprimir sintomas associados com doenças mitocondriais, tais como ataxia de friedreich (frda), neuropatia òtica hereditário de leber (lhon), atrofia ótica dominante (doa); miopatia mitocondrial, encefalopatia, lactacidose, acidene vascular cerebral (mela), síndrome de leigh ou síndrome de kearns-sayre (kss) com os compostos da fórmula i são revelados. métodos de modular, normalizar, ou intensificar o biomarcador de energia, como também compostos úteis para tais métodos são também revelados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40104410P | 2010-08-06 | 2010-08-06 | |
PCT/US2011/046630 WO2012019029A2 (en) | 2010-08-06 | 2011-08-04 | Treatment of mitochondrial diseases with naphthoquinones |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013002877A2 true BR112013002877A2 (pt) | 2016-05-31 |
Family
ID=45560075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013002877A BR112013002877A2 (pt) | 2010-08-06 | 2011-08-04 | tratamento de doenças mitocondriais com naftoquinonas |
Country Status (10)
Country | Link |
---|---|
US (1) | US20130345312A1 (pt) |
EP (1) | EP2600857A4 (pt) |
JP (2) | JP6045494B2 (pt) |
AU (1) | AU2011285619B2 (pt) |
BR (1) | BR112013002877A2 (pt) |
CA (1) | CA2807507A1 (pt) |
EA (1) | EA201300215A1 (pt) |
MX (1) | MX2013001469A (pt) |
SG (1) | SG187744A1 (pt) |
WO (1) | WO2012019029A2 (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2583087C (en) | 2003-09-19 | 2012-07-10 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
DK2564843T3 (en) | 2005-06-01 | 2019-03-11 | Bioelectron Tech Corp | Redox-active therapeutics for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers |
JP5374162B2 (ja) | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ, インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
PL3456707T3 (pl) | 2007-11-06 | 2020-09-21 | Ptc Therapeutics, Inc. | Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych |
US8952071B2 (en) | 2008-01-08 | 2015-02-10 | Edison Pharmaceuticals, Inc. | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
EP2303824B1 (en) | 2008-06-25 | 2015-03-25 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
US8314153B2 (en) | 2008-09-10 | 2012-11-20 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
WO2010045220A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
EP3450431B1 (en) | 2008-10-28 | 2023-09-13 | PTC Therapeutics, Inc. | Process for the production of alpha-tocotrienol and derivatives |
EA031126B1 (ru) | 2009-04-28 | 2018-11-30 | Биоэлектрон Текнолоджи Корпорейшн | Способ лечения доминантной атрофии зрительного нерва токотриенол-хинонами |
US9464016B2 (en) | 2011-06-14 | 2016-10-11 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
WO2013013078A1 (en) | 2011-07-19 | 2013-01-24 | Edison Pharmeceuticals, Inc. | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
EP2872497B2 (en) | 2012-07-12 | 2019-10-09 | Khondrion Ip B.V. | Chromanyl derivatives for treating mitochondrial disease |
WO2014039917A1 (en) * | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Benzoquinone derivatives for treating oxidative stress disorders |
CN110339339A (zh) * | 2013-03-01 | 2019-10-18 | 康德生物医疗技术公司 | 治疗线粒体疾病的方法 |
JP6518197B2 (ja) | 2013-03-01 | 2019-05-22 | ステルス バイオセラピューティックス コープ | バース症候群の予防または治療のための方法及び組成物 |
US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
WO2014145116A2 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
US10047395B2 (en) | 2013-06-26 | 2018-08-14 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
CA2936146A1 (en) * | 2014-01-06 | 2015-07-09 | Stealth Biotherapeutics Corp | Methods and compositions for preventing or treating dominant optic atrophy |
PL3233786T3 (pl) | 2014-12-16 | 2022-06-13 | Ptc Therapeutics, Inc. | Polimorficzne i amorficzne postacie (r)-2-hydroksy-2-metylo-4-(2,4,5-trimetylo-3,6-dioksocykloheksa-1,4-dienylo)butanoamidu |
US10815211B2 (en) | 2015-10-08 | 2020-10-27 | Khondrion Ip B.V. | Compounds for treating mitochondrial disease |
JP7117241B2 (ja) | 2015-12-16 | 2022-08-12 | ピーティーシー セラピューティクス, インコーポレイテッド | 混合されたトコール組成物からアルファ-トコトリエノールを富化するための改良された方法 |
CN108712903A (zh) | 2015-12-17 | 2018-10-26 | 生物电子技术有限公司 | 用于治疗氧化应急障碍的氟烷基、氟代烷氧基、苯氧基、杂芳氧基、烷氧基和胺1,4-苯醌衍生物 |
JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩 |
WO2018184706A1 (en) | 2017-04-05 | 2018-10-11 | Khondrion Ip B.V. | Novel treatment of mitochondrial diseases |
CN110582480B (zh) | 2017-04-21 | 2023-11-10 | 塔斯马尼亚大学 | 治疗化合物和方法 |
JP2021533115A (ja) | 2018-07-29 | 2021-12-02 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメントMusc Foundation For Research Development | 神経疾患またはミトコンドリア疾患の処置のための化合物 |
KR20210076956A (ko) | 2018-10-17 | 2021-06-24 | 피티씨 테라퓨틱스, 인크. | α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온 |
WO2020152336A1 (en) | 2019-01-25 | 2020-07-30 | Universitat Autonoma De Barcelona | Cannabidiol and/or derivatives thereof for use in the treatment of mitochondrial diseases |
KR20220078644A (ko) | 2019-10-04 | 2022-06-10 | 스텔스 바이오테라퓨틱스 인코포레이티드 | 미토콘드리아 질환 치료를 위한 바티퀴논의 퀴논-, 히드로퀴논- 및 나프토퀴논-유사체 |
US12037350B2 (en) | 2020-04-03 | 2024-07-16 | Stealth Biotherapeutics Inc. | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia |
IT202100006065A1 (it) * | 2021-03-15 | 2022-09-15 | Univ Degli Studi Padova | Composto per l’uso nel metodo di trattamento delle malattie mitocondriali da disfunzione dei complessi i, ii, iii della catena respiratoria |
EP4366700A1 (en) | 2021-07-08 | 2024-05-15 | PTC Therapeutics, Inc. | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0117326D0 (en) * | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
JP2003226639A (ja) * | 2002-01-31 | 2003-08-12 | Hisamitsu Pharmaceut Co Inc | 神経成長因子活性増強剤としてのビタミンk類を含む医薬組成物およびその使用 |
US20040087527A1 (en) * | 2002-10-31 | 2004-05-06 | Day Brian J. | Methods for treatment of thiol-containing compound deficient conditions |
DK2564843T3 (en) * | 2005-06-01 | 2019-03-11 | Bioelectron Tech Corp | Redox-active therapeutics for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers |
RU2318500C2 (ru) * | 2005-10-18 | 2008-03-10 | Общество С Ограниченной Ответственностью "Митотехнология" | Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели |
JP5374162B2 (ja) * | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ, インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
KR20080047959A (ko) * | 2006-11-27 | 2008-05-30 | 주식회사 엠디바이오알파 | 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물 |
WO2009111576A2 (en) * | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
US8314153B2 (en) * | 2008-09-10 | 2012-11-20 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
WO2011082355A1 (en) * | 2009-12-31 | 2011-07-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
WO2012019032A1 (en) * | 2010-08-06 | 2012-02-09 | Ampere Life Sciences, Inc. | Treatment of mitochondrial diseases with vitamin k |
WO2012170773A1 (en) * | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
-
2011
- 2011-08-04 EA EA201300215A patent/EA201300215A1/ru unknown
- 2011-08-04 WO PCT/US2011/046630 patent/WO2012019029A2/en active Application Filing
- 2011-08-04 CA CA2807507A patent/CA2807507A1/en not_active Abandoned
- 2011-08-04 JP JP2013523342A patent/JP6045494B2/ja not_active Expired - Fee Related
- 2011-08-04 BR BR112013002877A patent/BR112013002877A2/pt not_active Application Discontinuation
- 2011-08-04 SG SG2013009212A patent/SG187744A1/en unknown
- 2011-08-04 MX MX2013001469A patent/MX2013001469A/es unknown
- 2011-08-04 US US13/814,721 patent/US20130345312A1/en not_active Abandoned
- 2011-08-04 EP EP11815334.5A patent/EP2600857A4/en not_active Withdrawn
- 2011-08-04 AU AU2011285619A patent/AU2011285619B2/en not_active Ceased
-
2016
- 2016-01-04 JP JP2016000265A patent/JP2016041772A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG187744A1 (en) | 2013-03-28 |
WO2012019029A3 (en) | 2013-08-15 |
JP2013541502A (ja) | 2013-11-14 |
WO2012019029A2 (en) | 2012-02-09 |
JP2016041772A (ja) | 2016-03-31 |
EA201300215A1 (ru) | 2013-07-30 |
CA2807507A1 (en) | 2012-02-09 |
EP2600857A2 (en) | 2013-06-12 |
JP6045494B2 (ja) | 2016-12-14 |
EP2600857A4 (en) | 2014-06-11 |
AU2011285619A1 (en) | 2013-03-07 |
MX2013001469A (es) | 2013-05-14 |
US20130345312A1 (en) | 2013-12-26 |
AU2011285619B2 (en) | 2016-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013002877A2 (pt) | tratamento de doenças mitocondriais com naftoquinonas | |
EP2601168A4 (en) | TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K | |
CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
PE20151023A1 (es) | Triazolopirazinas | |
CU20200099A7 (es) | Compuestos derivados sustituidos de ácidos 6-carboxílicos de bencimidazoles y 4-aza-, 5-aza y 7-aza- benzimidazoles como agonistas glpr-1 útiles para el tratamiento o prevención de enfermedades cardiometabólicas y asociadas | |
CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
CY1119531T1 (el) | Ενωσεις και συνθεσεις για την ρυθμιση της δραστηριοτητας toy egfr | |
CO2017011851A2 (es) | Compuestos novedosos | |
DOP2016000017A (es) | Nuevos compuestos tricíclicos | |
DOP2015000157A (es) | Lactamas fusionadas de arilo y heteroarilo | |
EA201101668A1 (ru) | Редокс-активные терапевтические средства для лечения митохондриальных нарушений | |
ECSP14018375A (es) | 6-alquinilo piridinas como miméticos smac | |
CL2015002556A1 (es) | Inhibidores de la ruta de quinurenina | |
EA201001119A1 (ru) | Производные (гет)арил-п-хинона для лечения митохондриальных болезней | |
MX2018007389A (es) | Derivados de fluoroalquil-, fluoroalcoxi-, fenoxi-, heteroariloxi-, alcoxi- y amina-1,4-benzoquinona para tratamiento de trastornos de estres oxidativo. | |
BR112016029612A2 (pt) | compostos de di-hidroisoquinolinona substituídos | |
UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
CO7230336A2 (es) | Inhibidores de indazol de la ruta de señalización de wnt y usos terapeúticos de los mismos | |
UY34593A (es) | Miméticos sintéticos de apelina para el tratamiento de falla cardiaca | |
CO6781507A2 (es) | Novedosos derivados heterociclicos | |
CR20140205A (es) | Derivados de 8-carbamoil-2-(2,3-pirid-6-ilo di sustituido) -1,2,3,4- tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes | |
UY33199A (es) | 5-alquinil-pirimidinas. | |
CY1117706T1 (el) | Παραγωγα οξαζολινης και ισοξαζολινης ως ρυθμιστες crac | |
DOP2012000030A (es) | Polipéptidos del factor ix modificados y usos de los mismos | |
PE20170193A1 (es) | Derivados de 6-alquinil-piridina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |